Home›Stock Screener›AstraZeneca Pharma

AstraZeneca Pharma Share Price Today | Stock Price & AstraZeneca Pharma Share Screener

ASTRAZEN Pharmaceuticals & Biotechnology
Live Share Price NSE
₹6113.00
▲ 69.50 (1.15%)
2026-11-19 00:00:00
Live Share Price BSE
₹6120.45
▲ 113.50 (1.89%)
2026-11-19 00:00:00

As of November 19, 2026, the live AstraZeneca Pharma share price (NSE: ASTRAZEN) is ₹6,113.00 on NSE and ₹6,120.45 on BSE, up 1.15% from the previous close, with shares trading between ₹5,994.50 and ₹6,148.50 in today's trading session, and a 52-week range of ₹5,719.50–₹9,226.50. Track AstraZeneca Pharma marketcap in USD to gauge the company's total market size. Use the AstraZeneca Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today AstraZeneca Pharma opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹2,639 and net income of ₹178, with EBITDA of ₹271, an operating margin of 9.0% and a profit margin of 6.7%.

AstraZeneca Pharma Market Cap ₹15,108.75 Cr.
ASTRAZEN P/E Ratio (TTM) 86.70
AstraZeneca Pharma P/B Ratio 17.54
EPS (TTM) ₹75.01
Dividend Yield 0.58%
Debt to Equity 0.09
ASTRAZEN 52 Week High ₹9226.50
AstraZeneca Pharma 52 Week Low ₹5719.50
Operating Margin 9.00%
Profit Margin 6.74%
ASTRAZEN Revenue (TTM) ₹2,639.00
EBITDA ₹271.00
Net Income ₹178.00
Total Assets ₹1,989.00
Total Equity ₹873.00

AstraZeneca Pharma Share Price Chart

Track the current stock price of AstraZeneca Pharma with an interactive chart. Analyse ASTRAZEN share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete AstraZeneca Pharma stock quote in one place.

The quote of ₹6,113.00 sits between the 52-week low of ₹5,719.50 and the 52-week high of ₹9,226.50, and the latest session moved 1.15% from the previous close.

AstraZeneca Pharma Company Profile - Fundamental Screener

Screen AstraZeneca Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ASTRAZEN shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with Shilpa Divekar Nirula listed as chairperson or CEO, and it trades under ISIN INE203A01020.

Business Overview

AstraZeneca Pharma India Limited is a biopharmaceutical company incorporated in 1979. It manufactures, distributes, and markets pharmaceutical products, focusing on cardiovascular, renal and metabolism, oncology, and respiratory diseases. The company operates in the healthcare segment and provides clinical trial services to an overseas group company. Key products include Forxiga for...more

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

Chairperson/CEO Shilpa Divekar Nirula
ISIN INE203A01020

AstraZeneca Pharma Balance Sheet Screener

Screen ASTRAZEN balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹1,989, up from ₹1,518 in 2025.

Latest statistics put total assets at ₹1,989 and shareholder funds at ₹873, with a leverage ratio of 0.09.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 1,989 1,518 1,078 985 857 775 706 562 461 416
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 118 64 67 69 75 81 72 75 76 87

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 135 45 9 12 13 15 15 2 7 2
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 873 770 712 589 511 456 364 301 247 223
Share Capital 5 5 5 5 5 5 5 5 5 5
Reserves & Surplus 868 765 707 584 506 451 359 296 242 218

AstraZeneca Pharma Income Statement Screener - Profit & Revenue Analysis

Screen AstraZeneca Pharma income statement and profit fundamentals. Analyze ASTRAZEN quarterly results. AstraZeneca Pharma reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹2,639 and net profit was ₹178, equal to earnings per unit of ₹71.10, at an operating margin of 9%.

In that period expenses were ₹2,368, interest cost ₹7 and tax ₹54. The next period listed, 2026-March, shows revenue of ₹2,304 and net profit of ₹188.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Revenue and Expenses

Revenue 2,639 2,304 1,757 1,330 1,029 820 826 845 745 583 558 571 523
Expenses 2,368 2,014 1,462 1,111 838 719 678 711 657 525 507 547 529

Operating Costs and Margins

EBITDA 271 291 295 219 191 101 148 134 88 59 51 23 -6
Operating Profit % 9.00% 12.00% 15.00% 14.00% 16.00% 11.00% 17.00% 15.00% 10.00% 8.00% 7.00% 3.00% -2.00%
Depreciation 20 29 40 15 16 17 20 19 15 15 16 17 15
Interest 7 5 2 1 1 1 1 1 0 0 0 0 0

Profit and Earnings

Profit Before Tax 244 252 156 220 134 83 127 114 73 44 36 6 -21
Tax 54 65 41 58 35 21 34 42 18 18 15 1 0
Net Profit 178 188 116 162 99 62 93 72 54 26 20 5 -21
EPS 71.10 75.01 46.30 64.60 39.70 24.60 37.30 28.90 21.80 10.40 8.00 2.10 -8.34

AstraZeneca Pharma Cash Flow Screener - Liquidity Fundamentals

Screen ASTRAZEN cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities used ₹15, and net cash flow was an outflow of ₹88.

Over the same period, investing activities provided ₹19 and financing activities used ₹92.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities -15 65 28 58 101 105 87 55 9 38
Investing Activities 19 31 22 18 5 173 -171 4 -9 0

Financing and Net Cash

Financing Activities -92 -66 -44 -25 -10 -9 -6 0 0 0
Net Cash Flow -88 31 5 52 96 269 -90 59 -1 38

AstraZeneca Pharma Shareholding Pattern Screener

See AstraZeneca Pharma shareholding pattern with promoter, FII, and DII holdings. Check AstraZeneca Pharma promoter holding and ownership changes for ASTRAZEN on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Sept, promoters held 75.00%, foreign institutions 2.64%, domestic institutions 7.09% and the public 12.82%, spread across 30,408 shareholders.

The shareholder count was 30,408 in 2026-Sept, compared with 29,338 in 2026-Jun.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec

Promoter Holding

Promoter Holding 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00%

Institutional Investors

FII Holding 2.64% 2.68% 2.78% 2.71% 2.74% 3.03% 2.89% 2.93%
DII Holding 7.09% 6.08% 5.80% 5.56% 5.26% 4.56% 4.65% 5.22%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 12.82% 13.76% 13.88% 14.14% 14.39% 15.18% 15.16% 14.62%
Other Holding 2.45% 2.48% 2.55% 2.59% 2.61% 2.23% 2.31% 2.24%
Shareholder Count 30,408 29,338 29,007 31,551 32,914 34,378 32,466 27,322

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by AstraZeneca Pharma. AstraZeneca Pharma dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹36.00 per unit for 2026-March, a yield of 0.58%, compared with ₹32.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹36.00, ₹32.00 and ₹24.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹36.00 0.58%
2025-March ₹32.00 0.41%
2024-March ₹24.00 0.28%
2023-March ₹16.00 0.30%
2022-March ₹10.00 0.31%
2021-March ₹2.00 0.08%
2020-March ₹1.00 0.03%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

AstraZeneca Pharma Stock Index Membership - Nifty & Sensex

See which indices include AstraZeneca Pharma stock. Check ASTRAZEN index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 18 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX MSL400.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
NIFTY 500
NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100
NIFTY MIDSML 400
NIFTY SMALLCAP250 MOMENTUM QUALITY 100
NIFTY SMALLCAP250 QUALITY 50
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
NIFTY500 MULTICAP MOMENTUM QUALITY 50
NIFTY500 SHARIAH

AstraZeneca Pharma Market Events Screener - Corporate Actions

Get AstraZeneca Pharma corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check AstraZeneca Pharma stock events that may affect ASTRAZEN share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 5, 2026, with a record date of November 5, 2026.

It is followed by Quarterly Result Announcement dated August 10, 2026 and Annual General Meeting dated August 10, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-05 2026-11-05 Quarterly Result Announcement NA 1.10%
2026-08-10 2026-08-10 Quarterly Result Announcement NA -1.31%
2026-08-10 2026-08-10 Annual General Meeting NA 2.06%
2026-07-31 2026-07-31 Dividend ₹ 36.00 /share -8.02%
2026-05-26 2026-05-26 Quarterly Result Announcement NA 1.20%
2026-02-11 2026-02-11 Quarterly Result Announcement NA 4.80%
2025-11-07 2025-11-07 Quarterly Result Announcement NA -1.29%
2025-08-14 2025-08-14 Quarterly Result Announcement NA -6.00%
2025-08-14 2025-08-14 Annual General Meeting NA -4.71%
2025-07-18 2025-07-18 Dividend ₹ 32.00 /share 18.54%
2025-05-30 2025-05-30 Quarterly Result Announcement NA -0.03%
2025-02-11 2025-02-11 Quarterly Result Announcement NA 8.88%
2024-11-13 2024-11-13 Quarterly Result Announcement NA 3.57%
2024-08-08 2024-08-08 Annual General Meeting NA 7.26%
2024-07-05 2024-07-05 Dividend ₹ 24.00 /share 18.44%

AstraZeneca Pharma Competitors Screener - Peer Stocks Comparison

Screen ASTRAZEN competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 449,036 40.80 61,674 12.69% 11,565 60.77
Divis Laboratories 293,316 87.70 11,067 13.95% 2,568 65.94
Torrent Pharmaceuticals 175,376 84.70 13,886 20.34% 2,138 42.26
Laurus Labs 125,488 94.90 6,868 22.01% 890 55.82
Zydus Life Science 119,900 27.90 27,658 17.64% 5,026 55.22
Dr Reddys Laboratories 116,705 42.00 35,059 3.90% 4,158 73.09
Cipla 114,474 39.20 29,045 2.24% 3,870 62.07
Mankind Pharma 108,424 47.50 14,636 14.85% 1,938 62.66
Aurobindo Pharma 103,355 25.90 34,145 5.56% 3,503 60.69
Lupin 90,173 17.10 29,039 26.75% 5,356 44.73

AstraZeneca Pharma Company Announcements - News & Reports Screener

Screen ASTRAZEN latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 19, 2026.

The next most recent announcements are dated November 19, 2026 and November 19, 2026.

Date Update Actions
2026-11-19 Revised Submission With Functional Link - Letter Of Intent With Strand Life Sciences Private Limited - Disclosure Of Linkedin Communication -
2026-11-19 Letter Of Intent With Strand Life Sciences Private Limited - Disclosure Of Linkedin Communication -
2026-11-19 Shareholder Meeting / Postal Ballot-Notice of Postal Ballot -
2026-11-07 Launch Of Datopotamab Deruxtecan (Brand Name: Datverzo) -
2026-11-05 Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Update -
2026-11-05 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-11-05 Determination Of Materiality - Details Of Key Managerial Personnel -
2026-11-05 Appointment/ Change In Designation Of Senior Management Personnel -
2026-11-05 Appointment Of Chief Financial Officer -
2026-11-05 Board Meeting Outcome for Outcome Of The Board Meeting Held On Thursday November 5 2026 -
2026-11-02 Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order -
2026-10-30 Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Thursday November 5 2026 -
2026-10-27 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-16 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-10-16 Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot -
2026-10-16 Announcement under Regulation 30 (LODR)-Credit Rating -
2026-09-18 Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order -
2026-09-15 Closure of Trading Window -
2026-09-15 Information Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Resignation Of Senior Management Personnel -
2026-09-02 Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Disclosure Of ESG Rating -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹6,113.00, within a 52-week range of ₹5,719.50 to ₹9,226.50. The P/E ratio is 86.70 and the P/B ratio is 17.54, with earnings per unit of ₹75.01. Market capitalisation stands at ₹15,108.75 Cr and the dividend yield is 0.58%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.